Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...

Viking Therapeutics is a clinical-stage biotech that's looking to compete with Lilly in weight loss treatment. Viking recently revealed plans to develop an obesity treatment that could be superior ...

About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the ...

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific pharmaceutical operation in my eyes. In addition to the unprecedented growth ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics VKTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $164.00. The company’s shares closed yesterday at $55.06.